News - Boehringer Ingelheim, Tradjenta

Filter

Popular Filters

Type 2 diabetes market to reach $38.8 billion by 2019

25-10-2013

The global type 2 diabetes market is expected to expand from $20.4 billion in 2012 to $38.8 billion by…

Boehringer IngelheimDiabetesEli LillyEuropeGemigliptinMarkets & MarketingNesinaNorth AmericaPharmaceuticalTakeda PharmaceuticalsTradjenta

Global type 2 diabetes market to reach $38.8 billion by 2019

25-09-2013

The global type 2 diabetes market is expected to grow from $20.4 billion in 2012 to $38.8 billion by…

Boehringer IngelheimDiabetesEli LillyEuropeGemigliptinLG Life SciencesMarkets & MarketingNesinaNorth AmericaPharmaceuticalTakeda PharmaceuticalsTradjenta

Positive Ph III data for Trajenta in elderly type 2 diabetes patients

15-08-2013

Elderly people with type 2 diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4)…

Boehringer IngelheimDiabetesEli LillyPharmaceuticalResearchTradjentaTrajenta

EU regulator finds no added pancreatic risks for GLP-1 diabetes drugs

26-07-2013

Having finalized a review of glucagon-like peptide 1 (GLP-1)-based diabetes therapies, the European Medicines…

AstraZenecaBoehringer IngelheimBristol-Myers SquibbBydureonDiabetesEli LillyEuropeJanuviaMerck & CoNovo NordiskOnglyzaPharmaceuticalRegulationTradjentaVictoza

FDA approves Boehringer and Lilly's Tradjenta and Jentadueto labeling to reflect pancreatitis risk

21-06-2013

German family-owned Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY) revealed yesterday (June…

Boehringer IngelheimDiabetesEli LillyJentaduetoNorth AmericaPharmaceuticalRegulationTradjenta

FDA approves expanded use of Boehringer and Lilly's Tradjenta

20-08-2012

German family-owned drug major Boehringer Ingelheim and US partner and Eli Lilly (NYSE: LLY) said on…

Boehringer IngelheimDiabetesEli LillyNorth AmericaPharmaceuticalRegulationTradjenta

Highlights of American Diabetes Association meeting

11-06-2012

The weekend saw a flood of new data on diabetes drug candidates and currently approved treatments presented…

Boehringer IngelheimDegludecDiabetesEli LillyempagliflozinLyxumiaNovo NordiskPharmaceuticalResearchSanofiTradjentaVictoza

Boehringer/Lilly’s linagliptin demonstrates durable efficacy over two years

19-09-2011

Results of a 102 week Phase III study for linagliptin (trade named Trajenta in Europe and Tradjenta in…

Boehringer IngelheimDiabetesEli LillyPharmaceuticalResearchTradjentaTrajenta

Boehringer and Lilly’s Trajenta approved for type 2 diabetes in Europe

26-08-2011

Following a positive European Medicines Agency advisory committee recommendation two is months ago, Independent…

Boehringer IngelheimDiabetesEli LillyEuropePharmaceuticalRegulationTradjentaTrajenta

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top